HPV18 E6 Antibody
Based on 1 Customer Validation
HPV18 E6 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to HPV18 E6.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
IHC-P, IHC-F, ELISA, IF-Tissue
-
Reactivity :
HPV18
-
Formulation:
Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
-
Conjugation:
Non-conjugated
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
IHC-F
IHC-F: Immunohistochemistry-Frozen
|
IF-Tissue
IF-Tissue: Immunofluorescence-Tissue
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|
| Dilution Ratio | 1:100-500 | 1:100-500 | 1:100-500 | 1:5000-10000 |
Product Details
HPV18 E6 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to HPV18 E6.
-
Host Rabbit
-
Clonality Polyclonal
-
Species ReactivityHPV18
-
Observed Molecular WeightObserved band size: 14 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 12 kDa
KLH conjugated synthetic peptide derived from HPV18 E6 : 75-158/158
affinity purified
Non-conjugated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
HPV18 E6 is the core oncoprotein encoded by high-risk human papillomavirus type 18, approximately 150-160 aa. It contains two zinc finger domains and a C-terminal PDZ binding motif. It has no enzymatic activity itself and exerts its carcinogenic effect by hijacking host proteins. Its core function is to form a heterodimer with the E3 ubiquitin ligase E6AP, recruiting and polyubiquitinizing p53, causing it to be degraded by the proteasome, thereby abolishing its "genome guardian" function. In addition, E6 synergistically inhibits p53 through multiple mechanisms, including binding to CBP/p300, inhibiting p53 phosphorylation, and cytoplasmic isolation; it degrades PDZ domain tumor suppressor proteins such as DLG1, SCRIB, and MAGI via C-terminal PBM, disrupting cell polarity and tight junctions; it independently activates hTERT/telomerase to achieve cell immortalization; it degrades Bak to inhibit apoptosis; and it binds to IRF3 to achieve immune escape. E6 is a key driver and important target of cervical cancer (especially HPV18-related cervical adenocarcinoma, such as HeLa cells) and other HPV-related malignancies.
Documentation
-
Data Sheet (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)